Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Shannon Kelley Sells 360 Shares of Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) General Counsel Shannon Kelley sold 360 shares of the business’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total value of $155,498.40. Following the transaction, the general counsel directly owned 12,138 shares of the company’s stock, valued at $5,242,887.72. The trade was a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Madrigal Pharmaceuticals Stock Down 1.5%

MDGL stock traded down $6.51 during mid-day trading on Friday, reaching $432.83. The company had a trading volume of 440,127 shares, compared to its average volume of 375,225. The firm has a fifty day simple moving average of $492.64 and a 200 day simple moving average of $486.72. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($2.57) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. During the same period in the prior year, the firm posted ($2.71) earnings per share. The business’s quarterly revenue was up 210.8% compared to the same quarter last year. Analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MDGL. Groupama Asset Managment raised its holdings in Madrigal Pharmaceuticals by 11.6% during the fourth quarter. Groupama Asset Managment now owns 30,620 shares of the biopharmaceutical company’s stock worth $17,831,000 after purchasing an additional 3,176 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Madrigal Pharmaceuticals in the 4th quarter valued at $1,083,000. Invesco Ltd. boosted its holdings in shares of Madrigal Pharmaceuticals by 21.9% in the 4th quarter. Invesco Ltd. now owns 365,314 shares of the biopharmaceutical company’s stock valued at $212,737,000 after buying an additional 65,749 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the 4th quarter valued at $355,000. Finally, XTX Topco Ltd purchased a new position in shares of Madrigal Pharmaceuticals in the 4th quarter valued at $1,642,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MDGL shares. Zacks Research raised shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Bank of America decreased their price objective on shares of Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Canaccord Genuity Group boosted their target price on shares of Madrigal Pharmaceuticals from $526.00 to $587.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Truist Financial increased their target price on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, Piper Sandler raised their price target on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a research note on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $685.31.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.